Transmedics Group, Inc. · NASDAQ:TMDX
Transmedics — William Blair 2026
21 slides from Transmedics's conference presentation, June 2026
Slide 1: Establishing the New Standard of Care for Organ Transplantation
Establishing the New Standard of Care for Organ Transplantation Waleed Hassanein, MD President & CEO June 2026
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including growth initiatives and strategies, including potential timelines f
Slide 3: Organ Transplantation – Life Saving Procedure
Organ Transplantation – Life Saving Procedure Gold standard for treating end-stage organ failure Longest life expectancy & Most cost-effective treatment best quality of life for for the very expensive & patients suffering of end- chronic disease condition of stage organ failure organ failure 3
Slide 4: Cold Storage of Donor Organs – Significant Limitations
Cold Storage of Donor Organs – Significant Limitations Cold Storage Severe time dependent injury (Ischemia) – Time & distance limitations 4-7OC No organ optimization or improvement capabilities – Limits utilization No assessment capabilities – Limits utilization & donor pool 4
Slide 5: Ischemic Reperfusion Injury & Impact on Post-Transplant Outcomes – PGD, EAD, PNF
Ischemic Reperfusion Injury & Impact on Post- Transplant Outcomes – PGD, EAD, PNF Reported in ~25-50% in post-Tx. Complications Impacts short and long- term clinical outcomes Costly medical and surgical management Stehlik, et al. 2011 ISHLT Registry Report; JHLT Vol 30, NO 10, 2011 5 Cold ischemic p
Slide 6: Significant Underutilization of Donor Organs in U.S.
Significant Underutilization of Donor Organs in U.S. 18,000 17,004 15,000 Donors 12,000 Utilization Utilization 64% 63% 10,854 10,671 9,000 Donors = 21,341 6,000 Utilization Transplants Utilization 27% 20% 3,000 4,636 3,404 Lungs Hearts Livers Kidneys 0 Total Deceased Donors in 2024 6 Source: 2024 O
Slide 7: The OCS Technology’s Unique Capabilities
The OCS Technology’s Unique Capabilities Minimizes ischemic damage: Portable oxygenated blood-based perfusion Enables ex-vivo optimization and treatment of the organ: Maintain active metabolism & add enhancers Enables clinical diagnostic assessment of the donor organ: Maintain organs functioning out
Slide 8: TransMedics Organ Care System (OCS) – The Only Multi-organ Perfusion Platform
TransMedics Organ Care System (OCS ) – The Only Multi-organ Perfusion Platform OCS Kidney is in development & not yet FDA approved devices in the U.S. approved by FDA 8
Slide 9: Created the First National Organ Procurement Infrastructure
Created the First National Organ Procurement Infrastructure 19 TMDX clinical hubs across the USA 50+ Procurement surgeons >200 Clinical coordinators & support 9
Slide 10: Built an Integrated Air & Ground Transplant Dedicated Logistics Network in the USA
Built an Integrated Air & Ground Transplant Dedicated Logistics Network in the USA 22 Transplant dedicated planes 140+ Full time Pilots Highest Safety Standards 10
Slide 11: Developed a Secure Digital Ecosystem for Maximum Transparency
Developed a Secure Digital Ecosystem for Maximum Transparency Logistics Optimization Automated Engine Transplant Center Portal Scheduling Algorithms Command NOP Case Center Management Portal NOP Transplant Teams Application 11
Slide 12: OCS NOP Transplant Volume Growth – U.S.
OCS NOP Transplant Volume Growth – U.S. 25,000 60% 19,833 50% 20,000 18,894 17,680 15,830 40% # of Transplants 14,694 Adoption Rate 15,000 15,159 30% 26% 10,000 15,324 14,844 20% 20% 5,000 13% 10% 6% 5,139 3,735 2,356 0 986 0% 2022 2023 2024 2025 *All Donors and All Recipients are considered. OPTN d
Slide 13: Impact of TransMedics NOP on U.S. Transplant Volumes
Impact of TransMedics NOP on U.S. Transplant Volumes (Heart, Lung, & Liver) 2022-2025 20000 With TMDX NOP volume 18000 ~25% growth 16000 14000 Without TMDX NOP volume -0.9% growth 12000 2022 2023 2024 2025 13 Source: 2025 OPTN US National Data as of 1/14/2026
Slide 14: OCS NOP – The Highest Reported Utilization Rates for Transplants
OCS NOP – The Highest Reported Utilization Rates for Transplants 100% 95% 98% 97% 96% 90% 85% 80% 75% 70% 65% 60% 55% Liver Heart Lung 50% 14 Source: TransMedics OLP, OHP, & TOP Post Market Registry Reports
Slide 15: Long Runway of Profitable Growth
Long Runway of Profitable Growth Path to 20,000+ OCS Transplants 2026 2027 2028 2029+ Next-Gen OCS ENHANCE OCS Kidney Clinical Trial Gen-3 OCS Liver, Heart, Heart & DENOVO Lung and Lung FDA Approval of Next- Programs FDA approval of OCS Gen Heart & Lung Launching EU NOP Indications Kidne
Slide 16: Ongoing U.S. Next-Gen OCS Heart and Lung Programs
Ongoing U.S. Next-Gen OCS Heart and Lung Programs Enhancing organ function ex-vivo – Beyond Preservation Safe extended perfusion – Daytime heart and lung Txs. New Evidence – Aiming to prove superiority of OCS vs SCS 16
Slide 17: Meet TransMedics CHOPS
Meet TransMedics C H O P S Controlled Hypothermic Organ Preservation System Validated Temp. Range 4-11 OC Stable Temp Control for up-to 24 hours 17
Slide 18: U.S. Heart Transplants CY 2025 By Cross-Clamp Time
U.S. Heart Transplants CY 2025 By Cross-Clamp Time – Total 4,646 DBD Hearts >4 Hours DBD Hearts ≤4 OCS & DCD Hearts Hours CHOPS 18
Slide 19: Financial Performance Summary
Financial Performance Summary Total Revenue Trend Income / (Loss) from Operations Trend Annual Revenue ($M) 700 $ millions 109 605 600 37 500 442 400 (31) (29) 300 242 200 93 Guidance 100 26 30 0 Total FY26 $727M to $757M 2020 2021 2022 2023 2024 2025 Revenue 20% to 25% growth *Guidance as of May 5,
Slide 20: TransMedics Unparalleled Capabilities in Organ Transplantation
TransMedics Unparalleled Capabilities in Organ Transplantation Delivering Superior The One-of-a-Kind Clinical & Utilization TMDX Trident – End-to- Transplant Outcomes End Service Mission Driven with Strong Pipeline of Proven Execution Track Technical Innovation Record 20
Slide 21: Shaping the Future of Organ Transplantation
Shaping the Future of Organ Transplantation 2 1